The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve upon existing therapies.
The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve upon existing therapies.
